


Figura 4. Estructura Molecular de un gen discontinuo modelo. Se esquematizan los principales elementos que componen un gen proteina, típico de mamíferos.

del gen oBLG. El nuevo gen híbrido, empieza con el promotor y elementos de control de la expresión derivados del gen oBLG, a los que le siguen: (1) la región 5' no-traducible de oBLG; (2) la región 5' no-traducible del gen FIX humano; (3) codón de iniciación de la traducción y codones subsecuentes requeridos para la síntesis de FIX; (4) codón de terminación de la secuencia codificante para la proteína FIX; (5) secuencias 3' no-traducibles del gen FIX hasta antes de la señal de poliadenilación; (6) región 5' no-traducible y resto de las secuencias para la proteína oBLG. Para mayor claridad, este complicado arreglo de elementos genéticos se ilustra a continuación:



El gen quimérico se microinyectó en el pronúcleo de cigotos unicelulares de ovinos, lográndose generar cuatro animales transgénicos: dos machos y dos hembras. Se estudiaron a las hembras, las cuales portan alrededor de 10 copias por célula del gen quimérico cada una; éstas fueron apareadas por separado y cada una dió nacimiento a un cordero, los cuales también heredaron el transgen quimérico BLG-FIX. Durante la lactancia se colectó leche de cada oveja madre y ésta se analizó para determinar la presencia de FIX de origen humano. Este se detectó por radioinmunoanálisis en la leche de ambas hembras aunque a muy bajos niveles; aproximadamente 25ng/ml, es decir alrededor de 250 veces menos que la concentración normal del plasma humano. Es de esperarse que el refinamiento de las manipulaciones y construcciones genéticas requeridas para este tipo de sistemas de producción conduzcan a niveles mayores de producción (Clark, A.J. y cols. 1989).

Cuando se logren niveles de eficiencia de expresión comparable para bovinos se estaría hablando de producir, a partir de una sola vaca transgénica productora de 5 galones de leche dirarios, en el orden de 20 g de la proteína recombinante de interés al día.

2. Producción transgénica de activador tisular del plasminógeno humano en la leche de cabras.

Una segunda proteína de origen humano escogida para producirla por un rumiante bio reactor, es el activador tisular del plasminógeno, proteasa de uso clínico, pero cuya producción actual es costosa. Ha sido demostrado que esta proteasa disuelve efectivamente los coagulos de fibrina responsables de oclusiones coronarias.

Para generar cabras transgénicas, los embriones fueron recuperados lavando oviductos asociados con ovarios ovulados, através de una cánula y colectándolos en cajas de petri. Estos fueron microinyectados con el ADN complementario codificante para una variante glicosilada de acción mas prolongada del activador tisular del plasminógeno, bajo el control transcripcional del promotor del gen de la proteína ácida del suero de la leche.

De 29 crías obtenidas de 36 hembras a las que se les transfirieron quirúrgicamente a sus oviductos o úteros los embriones microinyectados, después de cultivarlos en el laboratorio por 72 horas, el transgen se detectó en una cría macho y otra hembra.

La cría transgénica hembra a tenido descendientes en dos ocasiones y de un total de cinco crías, una resultó transgénica. La leche colectada através de su lactación contenía activador tisular del plasminógeno de origen humano con actividad amidolítica comparable al material derivado de sistemas de producción basados en cultivo celular, pero a concentraciones de tan solo unos cuantos miligramos por litro. El diseño de un protocolo simple de purificación les permitió a los investigadores recobrar la proteína recombinante con un grado de pureza electroforética del 98% y un rendimiento total del 25%. Aunque las caracterizaciones de dicha proteína arrojaron diferencias en varios parámetros con respecto a la proteína producida mediante el sistema de producción convencional de cultivo de células de ratón, tales como el patrón de glicosilación, los efectos de dichos cambios en la farmacocinética, inmunogenicidad y otros, permanece aun por determinarse. Mas recientemente, se construyó un sistema de expresión usando el promotor del gen de la β-caseína caprina, así como secuencias flanqueantes de este gen, para expresar también la región codificante para el activador tisular del plasminógeno de origen humano, obteniéndose muchos mejores niveles de producción (Ebert y cols., 1992).

CONCLUSIONES Y PERSPECTIVAS

La década de los 90's se inicia con renovadas confianza y esperanza en la Biotecnología Animal. Después del éxito de la Biotecnología Molecular Industrial, que aporta ya varias proteínas recombinantes al mercado, ahora las granjas moleculares ofrecen producir valiosos agentes terapéuticos en grandes volúmenes y a bajos costos; sin duda que los rumiantes de granja jugarán un papel central en esta nueva era de la Biotecnología Animal.

Muchas son las posibilidades que se desprenden de la manipulación del genoma animal. Se contemplan entre otras: 1) Nuevas variedades con mayor velocidad de crecimiento y eficiencia de conversión alimenticia, 2) Animales resistentes a plagas y parásitos. 3) Animales biorreactores produciendo en su sangre o leche grandes cantidades de agentes terapéuticos, 4) Animales con importantes mejoras en sus capacidades metabólicas que les permitan por ejemplo degradar la celulosa. 5) Animales mejor adaptados al medio, 6) Animales con carne más magra, etc.

Paralelamente a estas manipulaciones ya en marcha, mucho se beneficiará la nueva Biotecnología Animal de las mejoras y desarrollos futuros de las tecnologías para generar y cultivar embriones in vitro y de las de partición y clonación de embriones. También muy importante serán los trabajos que actualmente se realizan en el reemplazo de genes por recombinación homóloga en células embrionarias pluripotenciales cultivadas in vitro, que luego se reincorporan en blastocistos.

AGRADECIMIENTOS

Expreso mi gratitud a todos los miembros de mi laboratorio y en especial a Atáulfo Martínez Torres por sus apoyos y valiosos comentarios, a la Facultad de Medicina de la U.A.N.L., al CONACYT y la SESIC-SEP, por apoyar nuestros trabajos en Biotecnología Animal y a Mirthala Páez por la elaboración del manuscrito.

REFERENCIAS

Alvírez-Quihui, L.E. (1990). Subclonación y expresión transitoria de los DNAs complementarios de las hormonas de crecimiento humana y bovina. Tesis Facultad de Ciencias Biológicas, U.A.N.L.

Bolívar, F., R. Rodríguez, P.J. Greene, M. Betlach, H. Heyneker, H.M. Boyer, J. Crosa y S. Falkow. (1977). Construction and characterization of new cloning vehicles. II. An multipurpose cloning system. *Gene*. 2:95-113.

Campo, M.S. (1985). Bovine papilloma virus DNA: An eukaryotic cloning vector. En *DNA cloning vol. II. A Practical Approach*. Editado por DM. Glover. IRL Press. 213-238.

Castro, F.O. y De La Fuente J. (1988). Animales transgénicos. Posibilidades biotecnológicas. *Interferón y Biotecnología*. 5:210-222.

Clark, A.J. Bessos, H., Bishop, J.O., Brown, P., Harris, S., Lathe, R. McClenaghan, M., Prowse, C., Simons, J.P., Whitelaw, C.B.A. y Wilmut, I. 1989. Expression of human anti-hemophilic factor IX in the milk of transgenic sheep. *BioTechnology* 7:487-492.

Cohen, S., Chang, A., Boyer, H. y Helling, R. (1973). Construction of biologically functional bacterial plasmids *in vitro*. *Proc. Natl. Acad. Sci. USA*, 70:3240-3244.

Ebert, K.M., Selgrath, J.P., DiTullio, P., Denman, J., Smith, T.E., Memon, M.A., Schindler, J.E., Monastersky, G.M., Vitale, J.A. y Gordon, K. (1992). Transgenic production of a variant of human tissue-type plasminogen activator in goat milk: generation of transgenic goats and analysis of expression. *Biotechnology* 9:835-838.

Friedman, J.S., Cofer, C.L., Anderson, C.L., Kushner, J.A., Gray, P.P., Chapman, G.E., Stuart, M.C., Lazarus, L., Shine, J. y Kushner, P.J. (1989). High expression in mammalian cells without amplification. *Biotechnology*. 7:359-362.

George, H.J., L'Italien, J.J., Pilacinski, W.P. Glassman, D.L. y Krzyzek, R.A. (1985). High-level expression in *Escherichia coli* of biologically active bovine growth hormone. *DNA*. 4:273-281.

Goeddel, D.V., D.G. Kleid, F. Bolivard, H. Heyneker, D. Yansura, R. Crea, T. Hirose, A. Kraszewski, K. Itakura, and A. Riggs. "Expression in *Escherichia coli* of chemically synthesized genes for human insulin." *Proc. Natl. Acad. Sci. USA*, 76:106-110.

Gordon, K., Lee, E., Vitale, J.A., Smith, A.E., Westphal, H., Hennighausen, L. (1987). Production of human tissue plasminogen activator in transgenic mouse milk. *BioTechnology* 5: 1183-1187.

Gray, G., Selzer, G., Buell, G., Shaw, P., Escanez, S., Hofer, S., Voegeli, P. y Thompson, C.J. (1984). Synthesis of bovine growth hormone by *Streptomyces lividans*. *Gene*. 32:21-30.

- Gray, G.L., Baldrige, J.S., McKeown, K.S., Heyneker, H.L. y Chang, C.N. (1985). Periplasmic production of correctly processed human growth hormone in *Escherichia coli*: natural and bacterial signal sequences are interchangeable. *Gene*. **39**:247-254.
- Hitzeman, R.M., Chen, C.Y., Dowbenko, D.J., Renz, M.E., Liu, C., Pai, R., Simpson, N.J., Kohr, W.J., Singh, A., Chisholm, V., Chisholm, V., Hamilton, R. y Chang, C.M. (1990). Use of heterologous and homologous signal sequences for secretion of heterologous proteins from yeast. *Methods in Enzymology*. **185**:421-440.
- Hsiung, H.M., Cantrell, A., Luirink, J., Oudega, B., Veros, A.J. y Becker, G.W. (1989). Use of Bacteriocin release protein in *Escherichia coli* for excretion of human growth hormone into the culture medium. *Biotechnology*. **7**:267-271.
- Jackson, D., Symons, R. y Berg, P. (1972). Biochemical method for inserting new genetic information into DNA of simian virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon of *Escherichia coli*. *Proc. Natl. Acad. Sci. USA*. **69**:290-2909.
- Kato, C., Kobayashi, T., Kudo, T., Furusato, T., Murakami, Y., Tanaka, T., Babe, H., Oishi, T., Ohtusuka, I., Ikehara, M., Yanosida, T., Kato, H., Moriyama, S. y Horikosi, K. (1987). Construction of an excretion vector and extracellular production of hGH in *Escherichia coli*. *Gene*. **54**:197-202.
- Keshnet, E., Rosner, A., Bernstein, Y., Gorecki, M. y Aviv, H. (1981). Cloning of bovine growth hormone gene and its expression in bacteria. *Nucleic Acids. Res.* **9**:19-30.
- Kopchick, J.J., Malavarca, R.H., Livelli, T.J. y Leung, F.C. (1985). Use of avian retrovirus bovine growth hormone DNA recombinants to direct expression of biologically active growth hormone by cultured fibroblasts. *DNA*. **4**:23-31.
- Leung, F.C., Jones, B., Steelman, S.L., Rosenblum, C.I., y Kopchick, J.J. (1986). Purification and physicochemical properties of a recombinant bovine growth hormone produced by cultured murine fibroblasts. *Endocrinology*. **119**:1489-1495.
- Leung, F.C., Bowen, D.L., y Chandler, D.P., (1990). Construction of a biologically active recombinant DNA plasmid containing a mouse metallothionein promoter and genomic bovine growth hormone gene. *Nucleic Acids. Res.* **18**:4948.
- Martial, J.A., Hallewell, R.A., Baxter, J.D. y Goodman, H.M. (1979). Human Growth hormone: complementary DNA cloning and expression in bacteria. *Science*. **205**:602-607.
- Palmiter, R.D., Brinster, R.L., Hammer, R.E., Trumbauer, M.C., Rosenfeld, M.G., Birnberg, N.C. y Evans, R.M. (1982). Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. *Nature*. **300**:611-615.
- Pursel, V.G., Pinkert, C.A., Miller, K.F., Bolt, D.J., Campbell, R.G., Palmiter, R.D., Brinster, R.L. y Hammer, R.E. (1989). Genetic engineering of livestock. *Science*. **244**:1281-1287.
- Ramírez-Solís, R., Reséndez-Pérez, D., Alvérez-Quihui, L.E., Rincón-Limas, D.E., Varela-Martínez, R., Martínez-Rodríguez, H.G. y Barrera-Saldaña, H.A. (1990). New vectors for the efficient expression of mammalian genes in cultured cells. *Gene*. **87**:291-294.
- Seeburg, P.H., Sias, S., Adelman, J., de Boer, H.A., Hayflick, J., Jhurani, P., Goeddel, D.V. y Heyneker, H.L. (1983). Efficient bacterial expression of bovine and porcine growth hormones. *DNA*. **2**:37-45.
- Selden, R.F., Howie K.B., Rowe, M.E., Goodman, H.H. y Moore, D. (1986). Human growth hormone as a reporter gene in regulation studies employing transient gene expression. *Mol. Cell. Biol.* **6**:3173-3179.

ETIOPATHOGENESIS OF EPIDIDYMITIS IN RAM LAMBS

Charles M. Scanlan D.V.M., Ph.D.
Department of Veterinary Pathobiology
College of Veterinary Medicine
Texas A&M University
College Station, Texas
United States of America

Introduction

Ram lamb epididymitis (LE) occurs primarily in virgin rams from 6 to 18 months of age and is caused by a variety of facultative anaerobic, gram-negative bacilli in the family Pasteurellaceae.^{1,3,4,7,9,11,19,20,28,30,33,36,38,39} In the early 1980's, LE was described in ram-producing flocks in the western United States as a distinct disease entity from ram epididymitis (RE) which occurs primarily in sexually mature rams and is caused by *Brucella ovis*, an obligate aerobic, gram-negative coccobacillus. Both LE and RE cause infertility in affected rams, resulting in significant economic losses to the sheep-producing industry. Although the etiologic agents and pathogenesis of the two diseases are markedly different, both LE and RE induce epididymal and testicular lesions, which are indistinguishable by palpation and gross pathology.⁷

The purposes of this report are (1) to provide an overview of LE with a historical review of the primary etiologic agents of the family Pasteurellaceae; (2) to update the taxonomic status of *Actinobacillus seminis* and the *Haemophilus-Histophilus* group; and (3) to characterize the phenotypic and biochemical properties of three new LE organisms that includes two *Actinobacillus*-like organisms and a capnophilic gram-negative bacillus, which were identified in our laboratory.

An Overview of Ram Lamb Epididymitis

Historically, five bacterial species and several organisms with phenotypic and biochemical characteristics of the family Pasteurellaceae have been associated with LE.^{3,4,9,11,19,28} *A. seminis* and *Histophilus ovis* are the two most frequently isolated organisms, while *A. actinomycetemcomitans*, *Haemophilus agni*, *H. somnus*, and several facultative anaerobic, gram-negative bacilli, which are frequently referred to as *Actinobacillus*-like organisms or *Haemophilus*-like organisms, are occasionally isolated from either the epididymal lesions or semen of affected rams. With the classification and taxonomic relationships of *H. agni*, *H. ovis*, and *H. somnus* being uncertain, these organisms were isolated from LE are commonly referred to as the *Haemophilus-Histophilus* group. Other organisms which are occasionally isolated from rams with epididymitis include *Actinomyces pyogenes*, *Bacteroides* species, *Corynebacterium pseudotuberculosis*, *Escherichia coli*, *Pasteurella* species, *Staphylococcus* species, and *Streptococcus* species. These organisms, however, are not considered specific causative agents of epididymitis in rams.

A. seminis was first reported as a new bacterial species in 1960, while *H. ovis*, *H. agni* and *H. somnus* were first reported in 1957, 1964, and 1969, respectively.^{2,3,17,23} The *A. seminis* isolate was from a ram with epididymitis; the *H. agni* and *H. ovis* isolates were from other ovine disease conditions; and the *H. somnus* isolate was from a bovine infection. Subsequently, *H. agni*, *H. ovis* as well as several *Actinobacillus*-like and *Haemophilus*-like organisms were isolated from either epididymal lesions or semen from rams with epididymitis.^{4,7,9,11,19,20,28,33,39} These gram-negative pleomorphs, which are considered to be either permanent or transient flora on the mucous membranes of the reproductive tract of young rams, cause ascending infections of the epididymes and occasionally the testicles and accessory sex organs.³⁵ The epididymal and testicular lesions develop most frequently during coldest periods of winter; however, specific factors that predispose the male reproductive organs to these organisms have not been clearly delineated. Regardless of the specific organism associated with LE, acute and chronic epididymitis and orchitis with infertility are the principal clinical manifestations.⁷ The effect on fertility may extend to complete sterility and is dependent upon the severity of infection, contamination by inflammatory and bacterial products, testicular involvement and semen production, patency of the genital ducts, and whether the infection is bilateral or unilateral. In yearling rams, the granulomatous lesions induced by *A. seminis* and *H. ovis* develop twice as frequently in the tails of the epididymis than as in the heads of the epididymis; however, distribution of epididymal lesions induced by *A. actinomycetemcomitans*, *H. agni*, the *Actinobacillus*-like organisms, and the *Haemophilus*-like organisms have not been clearly delineated.^{30,36,38,39} Some affected animals will have a severe orchitis with purulent exudate, but without any gross apparent involvement of the epididymes.

Today, LE is being reported in the major sheep-producing areas of the world, particularly in ram-producing flocks where mature and young rams are seldom mixed together.^{1,9,11,20,33,39} In yearling rams, LE is considered to be an economically important disease due to the adverse effect on ram fertility. This can lead to a decreased lamb crop or require a greater ram-ewe stocking ratio to sustain adequate crop production. Additional losses may be realized in purebred ram raising operations due to unsuitability of the affected ram for sale.

Most clinical diagnoses of LE are based on clinical signs and palpation of the epididymal lesions, while cultures of semen and the epididymal lesions are commonly used to confirm a diagnosis of LE, especially in *B. ovis* seronegative rams. The etiologic agents of LE are gram-negative pleomorphic bacilli, facultative anaerobic and capnophilic. These organisms exhibit good growth on blood agar when incubated in air with 10 percent carbon dioxide, but generally only fair growth when incubated either in air or under anaerobic conditions. Most organisms will not grow on MacConkey agar. Whenever possible the organisms are identified to species level based on their biochemical characteristics; however, the identification of these organisms has been difficult due to the lack of definitive characteristics. The distinction

between the two *Actinobacillus* species and the three organisms that comprise the *Haemophilus-Histophilus* group can be readily appreciated by morphologic appearance and biochemical traits; however, the *Actinobacillus*-like organisms and the *Haemophilus*-like organisms cause considerable confusion for the diagnostic bacteriologist.^{16,21,28}

Culling of rams with epididymal lesions is the primary method of control.⁴⁻⁶ Although there are no commercial vaccines available for LE, an experimental *A. seminis* bacterin has been demonstrated to reduce the incidence of LE under field conditions.¹²

Taxonomic Status of *Actinobacillus seminis* and the *Haemophilus-Histophilus* Group

In 1984, the first edition of *Bergey's manual of systematic bacteriology* classified *A. seminis*, *H. agni*, and *H. somnus* as "species incertae sedis", indicating that these organisms do not qualify for inclusion in the their respective genera, while *H. ovis* was not described as a distinct taxon.^{18,21} Subsequent investigations helped clarify the antigenic, biochemical, cytochemical, and genetic relationships among these organisms.^{10,13-16,22,24,27,29,31-32,34,37} Walker et al. determined that the deoxyribonucleic acid relatedness among *H. agni*, *H. ovis*, and *H. somnus* was very small but were genetically distinct from *A. seminis*.³⁴ They further stated that organisms comprising the *Haemophilus-Histophilus* group should be considered a single species. In 1990, Sneath et al. officially recognized *A. seminis* as a taxon in the genus *Actinobacillus*.²⁹ In 1991, Piechulla et al. further investigated the genetic relationships both between and within *A. seminis* and the *Haemophilus-Histophilus* group.²² They found that *A. seminis* was genetically distinct from the *Haemophilus-Histophilus* group; determined that the *Haemophilus-Histophilus* group was a single taxon but did not satisfy the genetic requirements to be classified in the genus *Haemophilus*; and officially reclassified the organisms of the *Haemophilus-Histophilus* group as *Histophilus ovis*, which was the original nomenclature assigned in 1956.²³

Actinobacillus-like Groups A and B Associated with LE

In 1989, Scanlan et al. described two *Actinobacillus*-like organisms from the semen of virgin rams with epididymitis as groups A and B.²⁸ The three strains in group A and the two strains in group B were nonmotile, predominantly gram-negative coccobacilli, and exhibited less pleomorphism than the American Type Culture Collection (ATCC) strain of *A. seminis* 15768. The colonial morphologies of groups A and B were similar to *A. seminis*, but were smaller in diameter and had a pale yellow color. Groups A and B, like *A. seminis*, were facultative anaerobic and capnophilic, did not grow on MacConkey agar, and were catalase-positive and oxidase-positive. Group A, like *A. seminis*, reduced nitrate but group B did not. Group A, group B, and *A. seminis* produced acid but no gas from glucose, and the utilization of other carbohydrates varied markedly both between and within

groups A and B. Group A utilized arginine, and *A. seminis* utilized ornithine; but group B did not utilize either arginine or ornithine. *A. seminis* produce acid phosphatase, alkaline phosphatase and beta-glucuronidase, but was negative for esterase (C4); group B produced acid phosphatase, alkaline phosphatase and esterase (C4); but group A was negative for these four enzymes.

In 1991, Scanlan and Healey evaluated the antimicrobial susceptibility characteristics of *A. seminis* ATCC 15678, fifteen *A. seminis* LE strains, and the three group B strains.²⁵ All strains were susceptible to amikacin, ampicillin, carbenicillin, cephalothin, chloramphenicol, erythromycin, gentamicin, kanamycin, neomycin, nitrofurantoin, novobiocin, penicillin, polymyxin B and tetracycline, but resistant to clindamycin. The *A. seminis* strains were susceptible to methicillin but resistant to bacitracin and sulfadiazine, whereas the group B strains were susceptible to bacitracin and sulfadiazine but resistant to methacillin. The antimicrobial susceptibility differences between *A. seminis* and group B, particularly to bacitracin which interferes with peptidoglycan synthesis and sulfadiazine which interferes with folic acid synthesis, provides a criterion to help distinguish these organisms.

Groups A and B had phenotypic and constituent biochemical properties of the family Pasteurellaceae, particularly those of currently defined species in the genus *Actinobacillus*; however, neither group A nor group B could be identified as species in the genera *Actinobacillus*, *Haemophilus*, or *Pasteurella* based on the taxonomic criteria in the first edition of *Bergey's manual of systematic bacteriology*.^{8,15,21}

Capnophilic Gram-negative Bacterium Associated with LE

In 1991, Scanlan and Healey described a capnophilic gram-negative bacillus (strain A2) from the semen of a virgin ram with epididymitis that had phenotypic and biochemical properties markedly different from those described for the facultative anaerobic, gram-negative bacilli in the family Pasteurellaceae, which have been traditionally associated with LE.²⁶

Strain A2 exhibited good growth on blood agar when incubated in air with 10 percent carbon dioxide, but failed to produce visible growth on MacConkey agar.²⁶ The bacterium also failed to produce visible growth on blood agar when incubated in air or in an anaerobic atmosphere. After 2 days incubation on blood agar in air with 10 percent carbon dioxide at 37°C, the colonies were raised, translucent, and nonhemolytic. Strain A2 was catalase-positive, oxidase-positive, reduced nitrite, and was asaccharolytic when tested for aerobic acid production from various monosaccharides, disaccharides, trisaccharides, alcohols, or glucosides. The bacterium also failed to utilize arginine, lysine, ornithine, or tryptophane.

In 1991, Healey et al. compared the outer membrane proteins (OMPs) of strain A2 with *A. seminis* ATCC strain 15768, *A. seminis* LE field strain As8C, and *Actinobacillus*-like group B strain D107, using sodium dodecyl sulfate polyacrylamide gel electrophoresis and two dimensional gel electrophoresis.¹⁶ The *A. seminis*